PROCID - Biosensor platform for rapid point-of-collection diagnosis of infectious diseases

Lead Participant: Intrinsiq Materials Limited


The PROCID programme is designed to prove the cost effective use of printed copper in low cost antibody based biosensors for disease detection, initially targeting the STD’s Chlamydia and Gonorrhea. This will provide a step change in ease of detection to combat and overcome the spread of infections. Key objectives include: development of low-cost biosensors based around immobilised antibodies, tailoring the biosensing system to rapidly detect the target organisms (Chlamydia and Gonorrhea) and development of a printing-based fabrication process for mass-manufacturing of the biosensors. The overall aim is to successfully integrate and deliver a functional prototype system that provides a low-cost sensor-based platform for rapid detection of infectious disease, with real potential for commercialisation by the industrial partners, and in doing so reduce NHS costs, increase detection rates, help combat major health hazards, and facilitate the implementation of tele-healthcare. The consortium consists of distinguished specialist partners – Leeds University, ELISHA Systems Ltd, The Ryedale Group, The Needham Group, Amies Innovation and P1 Technology, with Intrinsiq Materials leading the programme and providing their novel copper ink and sintering technology.

Lead Participant

Project Cost

Grant Offer

Intrinsiq Materials Limited, United Kingdom £340,520 £ 121,000


Amies Innovation Limited, CHESTERFIELD £84,695 £ 40,576
University of Leeds, United Kingdom £252,149 £ 252,149
P1 Technology Ltd, SHEFFIELD £98,025 £ 30,354
The Needham Group Ltd, WHITCHURCH £90,047 £ 19,646
Ryedale Group Limited, NORTH YORKSHIRE £120,631 £ 47,834


10 25 50